Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

IL-12 inhibitor

DRUG CLASS:

IL-12 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

lenalidomide (128)

lenalidomide (128)

›

No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval lenalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1	lenalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval lenalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + elotuzumab Sensitive: A1 - Approval lenalidomide + elotuzumab Sensitive : A1	lenalidomide + elotuzumab Sensitive: A1 - Approval lenalidomide + elotuzumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + daratumumab Sensitive: A1 - Approval lenalidomide + daratumumab Sensitive : A1	lenalidomide + daratumumab Sensitive: A1 - Approval lenalidomide + daratumumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + ixazomib Sensitive: A1 - Approval lenalidomide + ixazomib Sensitive : A1	lenalidomide + ixazomib Sensitive: A1 - Approval lenalidomide + ixazomib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lenalidomide + tafasitamab-cxix Sensitive: A1 - Approval lenalidomide + tafasitamab-cxix Sensitive : A1	lenalidomide + tafasitamab-cxix Sensitive: A1 - Approval lenalidomide + tafasitamab-cxix Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + carfilzomib Sensitive: A1 - Approval lenalidomide + carfilzomib Sensitive : A1	lenalidomide + carfilzomib Sensitive: A1 - Approval lenalidomide + carfilzomib Sensitive : A1
Chr del(5q)	Myelodysplastic Syndrome	Chr del(5q)	Myelodysplastic Syndrome	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	rituximab + lenalidomide + brentuximab vedotin Sensitive: A1 - Approval rituximab + lenalidomide + brentuximab vedotin Sensitive : A1	rituximab + lenalidomide + brentuximab vedotin Sensitive: A1 - Approval rituximab + lenalidomide + brentuximab vedotin Sensitive : A1